Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. Pylori eradication: A randomized trial

Journal of Clinical Gastroenterology

Volumn 47, Issue 3, 2013, Pages 228-232

  Georgopoulos, Sotirios ^a   Papastergiou, Vasilios ^b   Xirouchakis, Elias ^a   Laoudi, Foteini ^a   Lisgos, Philipos ^b   Spiliadi, Charikleia ^a   Papantoniou, Nikitas ^c   Karatapanis, Stylianos ^b  

^a Athens Medical P Faliron Hospital   (Greece)

^b General Hospital of Rhodes   (Greece)

^c Euromedica General Clinic   (Greece)

Author keywords

concomitant; eradication; Greece; H. Pylori; triple

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; UREA C 13;

ABDOMINAL DISCOMFORT; ADULT; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; VAGINA CANDIDIASIS; VOMITING;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE SODIUM; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UREA;

EID: 84873987880     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31826015b0     Document Type: Article

References (28)

1. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781.
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
4. Perri F, Villani MR, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard "Maastricht triple therapy". Aliment Pharmacol Ther. 2001;15:1023-1029.
5. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther. 2002;16:569-575.
6. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol. 2002;14:1237-1243.
7. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and secondline regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009;104:21-25.
8. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275-278.
9. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
10. Kim SY, Lee SW, Hyun JJ, et al. Comparative study of Helicobacter pylori eradication rates of 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol. 2012. (In press).
11. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507-514.
12. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146: 556-563.
13. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:923-931.
14. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooleddata analysis. Gut. 2007;56:1353-1357.
15. Treiber G, Ammon S, Schneider E, et al. Amoxicillin/ metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter. 1998;3:54-58.
16. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol. 1998;33:640-645.
17. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol. 2010;8:36-41.
18. Georgopoulos SD, Papastergiou V, Xirouchakis E, et al. Evaluation of a four drug, three antibiotic, non bismuth containing "concomitant" therapy as first-line H. pylori eradication regimen in Greece. Helicobacter. 2012;17:49-53.
19. Karatapanis S, Georgopoulos SD, Papastergiou V, et al. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial". Acta Gastroenterol Belg. 2011;74:407-412.
20. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther. 1999;13:497-501.
21. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter. 2000;5:88-93.
22. Nagahara A, Miwa H, Yamada T, et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:417-421.
23. Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118.
24. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604-617.
25. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect. 2002;8:388-896.
26. Mentis AF, Roma E, Pangalis A, et al. Susceptibilities of Helicobacter pylori strains isolated from children with gastritis to selected antibiotics. J Antimicrob Chemother. 1999;44: 720-722.
27. Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820-823.
28. Okada M, Nishimura H, KawashimaM, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther. 1999;13:769-774.